The Legal Basis for Compounding in the Philippines
Pharmacy compounding in the Philippines is authorized under Republic Act No. 10918, the Philippine Pharmacy Act of 2016. This is the primary law governing pharmacy practice in the country.
Section 30 of RA 10918 establishes two key provisions. First, no pharmaceutical product shall be compounded, dispensed, sold, or otherwise made available to the consuming public except through a retail drug outlet duly licensed by the FDA. Second, compounding and dispensing shall be done only by duly registered and licensed pharmacists, in accordance with current Good Manufacturing Practice, laboratory practice, Philippine Practice Standards for Pharmacists, and dispensing guidelines.
This means compounding is explicitly authorized by law, but it must occur within a licensed establishment and under the supervision of a registered pharmacist. These are not optional guidelines — they are statutory requirements with penalties for violation.
Section 33 of RA 10918 provides for fines of not less than ₱250,000 and up to ₱500,000, or imprisonment of one year and one day to six years, or both, for violations of Section 30.
FDA License to Operate (LTO) Requirements
The Philippine Food and Drug Administration, established under Republic Act No. 9711 (FDA Act of 2009), is the regulatory body that issues the License to Operate for all pharmaceutical establishments, including compounding pharmacies.
An LTO is required before a compounding pharmacy can legally operate. The application process requires the pharmacy to demonstrate that its facility meets FDA standards for the type of pharmaceutical activity being performed, a licensed Responsible Pharmacist has been designated to supervise operations, standard operating procedures are in place for all compounding activities, appropriate equipment, storage conditions, and environmental controls are maintained, and record-keeping systems are established.
The LTO must be renewed periodically and the FDA may conduct inspections to verify ongoing compliance.
For sterile compounding, the facility requirements are significantly more stringent than for non-sterile operations. The FDA will evaluate the cleanroom environment, air handling systems, environmental monitoring programs, and personnel training protocols.
Good Compounding Practice Standards
The Philippine regulatory framework requires compounding pharmacies to follow Good Manufacturing Practice, Good Laboratory Practice, and the Philippine Practice Standards for Pharmacists.
In practice, these translate to several operational requirements.
Ingredient quality. Active pharmaceutical ingredients and excipients must be of pharmaceutical grade, sourced from qualified suppliers, and accompanied by documentation (Certificates of Analysis) verifying identity, purity, and potency.
Formulation documentation. Every compound must be based on a documented formulation record that specifies all ingredients, quantities, equipment, procedures, and quality checks.
Compounding environment. The preparation area must be appropriate for the type of compounding being performed. For sterile preparations, this means a controlled cleanroom environment meeting recognized ISO classifications.
Personnel competency. Compounding must be performed by or under the direct supervision of a licensed pharmacist. Personnel must be trained in the specific techniques required for the type of compounding they perform.
Quality controls. Each preparation must undergo appropriate quality verification before dispensing. This includes visual inspection, measurement verification, and for sterile preparations, may include additional testing.
Record-keeping. Complete records must be maintained for every compound, including ingredient lot numbers, quantities used, preparation date, beyond-use date, pharmacist verification, and any quality test results.
These standards exist to ensure that every compounded preparation is safe, accurately prepared, and traceable.
Pharmacist Supervision and Accountability
Under RA 10918, the Responsible Pharmacist (RP) holds personal and professional accountability for all compounding activities that occur under their supervision.
The RP must hold a valid Certificate of Registration from the Professional Regulation Commission (PRC) and a current Professional Identification Card. They must be physically present during compounding operations and their original COR must be displayed prominently in the pharmacy.
The RP's responsibilities include verifying all prescriptions before compounding, supervising the compounding process, performing or overseeing quality checks on finished preparations, maintaining all required records, ensuring compliance with applicable regulations and practice standards, and reporting any quality issues or adverse events.
A compounding pharmacy cannot legally operate without a designated RP. The absence of an RP on-site during compounding hours is a regulatory violation.
Documentation and Record-Keeping
Record-keeping is a cornerstone of compounding pharmacy regulation. Every preparation must be fully traceable from raw materials to finished product.
Required documentation includes the prescription or physician's order, the formulation record (master formula and preparation worksheet), ingredient documentation (supplier COAs, lot numbers, expiration dates), preparation details (date, time, pharmacist, environmental conditions), quality check results, labeling information (patient/clinic, drug name, concentration, volume, beyond-use date, storage instructions, lot number), and dispensing records.
These records must be retained for a period specified by the FDA and must be available for inspection at any time.
For sterile compounding, additional documentation requirements include environmental monitoring results, personnel competency assessments, equipment certification records, and cleaning and disinfection logs.
Compounding vs Manufacturing Under Philippine Law
The distinction between compounding and manufacturing is a critical regulatory boundary.
Compounding is the preparation of a medication for an individual patient based on a specific prescription. It is a pharmacy function governed by RA 10918 and the FDA's LTO framework for pharmaceutical establishments.
Manufacturing is the large-scale production of medications for general distribution and sale. It is governed by a separate and more extensive regulatory framework that includes product registration with the FDA, compliance with Current Good Manufacturing Practice (cGMP) as defined by FDA administrative orders, pre-market approval for each product, and post-market surveillance requirements.
A compounding pharmacy that begins producing medications for general distribution without individual prescriptions crosses the line from compounding into manufacturing — and becomes subject to the manufacturing regulatory framework.
This distinction matters for prescribers: a compounded medication is a custom preparation for your specific patient. It is not a commercially available product and should not be treated as one.
What This Means for Prescribers
For physicians practicing in the Philippines, the regulatory framework supports your ability to prescribe compounded medications. You have the legal right to write prescriptions for compounded preparations, and a licensed compounding pharmacy has the legal authority to fill them.
Your responsibilities as a prescriber include writing clear, complete prescriptions that specify the medication, dose, form, and instructions, verifying that the compounding pharmacy holds a valid FDA LTO, confirming that a licensed RP supervises compounding operations, maintaining prescription records in your patient files, and monitoring patients receiving compounded medications as you would with any prescription drug.
The regulatory framework is designed to protect patients while enabling clinical flexibility. Working with a compliant compounding pharmacy gives you access to customized medications while maintaining the safety and documentation standards that protect both you and your patients.
ObraRx operates under the Philippine FDA's licensing framework. If you have questions about the regulatory requirements for compounding pharmacy or want to discuss a partnership, contact us.
FAQ
Q: What law governs compounding pharmacies in the Philippines?
A: Republic Act No. 10918 (Philippine Pharmacy Act of 2016) is the primary law. Section 30 authorizes compounding by licensed pharmacists. The Philippine FDA (under RA 9711) issues the License to Operate.
Q: What is an FDA License to Operate (LTO)?
A: An LTO is the operating license issued by the Philippine FDA that a compounding pharmacy must hold before it can legally compound and dispense medications.
Q: What is the penalty for compounding without a license in the Philippines?
A: Under Section 33 of RA 10918, violations carry fines of ₱250,000 to ₱500,000, imprisonment of one year and one day to six years, or both.
